Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd.
July 06, 2023
Share
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) intends to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million on April 25, 2023. Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) entered into an agreement to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million on April 28, 2023. Wuxi China Life Chengda Equity Investment Center (Limited Partnership) will acquire 6.76% stake and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) will acquire 1.08% stake in Jiangxi Zhenshiming.
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd on July 7, 2023.
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd.
ZHEJIANG CONBA PHARMACEUTICAL CO.,LTD. 
